Abstract 2558: Multi-omic single-cell assessment of castration-resistant prostate cancer patients receiving177Lu-PSMA-617 and pembrolizumab shows timing of radioligand therapy alters immune response
Anusha Muralidhar(Fred Hutch Cancer Center), Lawrence Fong(Fred Hutch Cancer Center), Shloka Shukla(Fred Hutch Cancer Center), Karen Law(Fred Hutch Cancer Center), Zenghua Fan(University of California, San Francisco), Rahul R. Aggarwal(University of California, San Francisco), David Y. Oh(University of California, San Francisco), Serena S. Kwek(University of California, San Francisco), Aram Lyu(Fred Hutch Cancer Center)
Cited by 0
Related Papers
Identification and Testing of Superior Reference Genes for a Starting Pool of Transcript Normalization in Arabidopsis
|Plant and Cell Physiology|2010|219
Predictors of responses to immune checkpoint blockade in advanced melanoma
|Nature Communications|2017|201
Microglia depletion and alcohol: Transcriptome and behavioral profiles
|Addiction Biology|2020|49
Sialylated glycoproteins suppress immune cell killing by binding to Siglec-7 and Siglec-9 in prostate cancer
|Journal of Clinical Investigation|2024|41